WW stock surges on GLP-1 medication support program

U.S. economy adds 64,000 jobs in November, delayed BLS data shows
Gold stabilizes after nonfarm payrolls; near record levels
Bitcoin price today: dips to $87k as risk remains frail after payrolls data
Top 6 chip stocks to buy for 2026, according to this semiconductor analyst
Investing.com --WW International Inc (NASDAQ:WW)stock jumped 11.5% Tuesday after the company, formerly known as Weight Watchers, announced a new integrated program providing comprehensive support for members using GLP-1 weight loss medications.
The weight management company unveiled its "GLP-1 Success Programme" designed to offer personalized nutrition guidance, tools to track weight loss and medication doses, strategies for managing side effects, and strength plans to help preserve muscle mass. The program will be available to members regardless of where they receive their GLP-1 prescriptions.
"As GLP-1 medications become available in more markets, people are increasingly looking for safe, expert guidance and support that fits the way they actually live," said Tara Comonte, CEO of Weight Watchers, adding that "members who use GLP-1s while engaging with the Weight Watchers programme lose more weight and report higher satisfaction and quality of life."
The company also introduced a redesigned digital experience featuring a new Weight Health Score, an AI-powered body scanner, exclusive fitness content, and adjustable "Modes" that adapt to members’ changing needs throughout their weight loss journey.
WW’s announcement comes as GLP-1 medications like Ozempic, Wegovy, Zepbound, and Mounjaro continue to gain popularity for weight management, creating new market opportunities for companies that can provide complementary support services.
The company is positioning itself to capitalize on the growing GLP-1 market while leveraging its 62-year history in behavioral weight management and community support.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.